Can I read 151 Combination NK-92MI^CD64^cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer on EtoBox?

151 Combination NK-92MI^CD64^cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer by Hintz, Hallie ;Walcheck, Bruce ;LeBeau, Aaron is a Medicine article available to read on EtoBox.

What is 151 Combination NK-92MI^CD64^cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer about?

Background Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease that has been largely resistant to immunotherapy. The lack of efficacy is due, in part, to the immunosuppressive tumor microenvironment and new therapeutic strategies for mCRPC must stimulate an antitumor response in the immunologically ‘cold’ tumors. Combination therapies that target both the tumor stroma and cancer cells could overcome the limitations of current immunotherapies and are demonstrated to be effective in multiple cancer models.1,2 NK cells are being explored as cell therapies and targeting NK cells to solid tumors can be improved by engineering the effector cells to express CD64, a high-affinity Fc receptor for human IgG. CD64 can capture soluble antibodies with 30–100x higher affinity than CD16A and mediates cell killing when antibody is bound.3 This docking platform allows for switchable targeting elements to redirect NK cells to multiple tumor antigens and facilitates the development of combination cell therapies. Methods NK-92MICD64 cell therapy was evaluated in combination with antibodies targeting the prostate tumor antigen tumor-associated calcium signal trans

Who reads 151 Combination NK-92MI^CD64^cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer?

Author

Hintz, Hallie ;Walcheck, Bruce ;LeBeau, Aaron

Publisher

BMJ Publishing Group Ltd

Published

2020

Language

EN

Field

Medicine (Health Sciences)